
BIO-MANUFACTURING INNOVATION SUMMIT
Summit took place 7 - 8 July 2022
See highlights below

Insight - Access - Engagement
Innovation & Partnering in Bio-Manufacturing
Past event: 7 - 8 July 2022
Thanks to our Partners, Speakers & Participants for making the launch edition such a success.
See you back at Rutgers,
in the new venue,
July 13 - 14, 2023
Here are a few snaps from the pilot edition
![]() Alberto CuitiñoInterim Dean, Rutgers School of Engineering Department Chair, Professor Mechanical & Aerospace Engineering, Rutgers University | ![]() Chris YochimHead of Business Development, National Institute for Innovation in Manufacturing BioPharmaceuticals - NIIMBL | ![]() Timothy T. Belski, MS, PMPBranch Chief, BioMaP PCI, Biomedical Advanced Research & Development Authority (BARDA) | ![]() Stelios C. TsinontidesDirector Office of Pharmaceutical Manufacturing Assessment (OPMA) Office of Pharmaceutical Quality Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration |
---|---|---|---|
![]() Shiv Krishnan & Rahul SinghviShiv Krishnan of Lonza, and Rahul Singhvi, CEO of Resilience; questions from the audience. | ![]() Rahul SingvhiCo-Founder & CEO Resilience | ![]() Rahul SinghviCo-Founder & CEO Resilience | ![]() Mark EmalfarbCEO & Founder, Dyadic International Inc. |
![]() Sarfaraz NiaziCo-Founder & CSO, Novel351K | ![]() Alastair FlorenceDirector, Future Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub | ![]() Alastair FlorenceDirector, Future Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub | ![]() Vipul DavéSenior Engineering Fellow, Strategy, Innovation & Deployment, Johnson & Johnson Supply Chain |
![]() Fernando MuzzioDistinguished Professor of Chemical and Biochemical Engineering, Rutgers University | ![]() Donald ZinnVice President, US Business Crossject | ![]() Investor PanelJustin Sperry, Pfizer Stephen Chambers, SOSV & IndieBio Tim Rollender, NJEDA Evergreen Fund |
Driving meaningful innovation, impact and value creation in Bio-Manufacturing and ensuring resilient, adaptable supply chains, efficient re-shoring, on-shoring and cutting edge pharma manufacturing solutions to meet demand and accelerate the development and production of essential novel therapeutics and vaccines, in the US and globally.
The Bio-Manufacturing Summit and partnering forum is co-organized by Broadreach Global and Host Partners Rutgers University, with support from NIIMBL - the National Institute for Innovation in Manufacturing Biopharmaceuticals, and our Global Innovation Partners MBHB LLC, Patent Docs, Mazards, and the BiotechGate Partnering Platform.

What solutions can technology transfer from the world-leading institutions and most innovative private companies provide? Which partners can provide the expertise to move these innovations to the market? How can industry and private companies reduce costs and accelerate their own programs? How to re-shore on on-shore rapidly and efficiently? What are the intellectual property and regulatory considerations? Engage with leading Bio-Manufacturing Innovators, selected projects, leading start-ups and growth companies, government, Investors, Industry, and leading innovation stakeholders and KOLs.
-
Hear from KOLs and leading experts.
-
See innovative technologies and company presentations.
-
Understand the strategic interests of key government agencies
-
Connect with leading investors
-
Engage with industry KOLs and decision-makers
-
Meet directly with key potential partners via the BiotechGate partnering platform and in-person meetings.
The one summit which brings together all key stakeholder groups in bio-manufacturing, matching transformational technologies and pioneering companies from around the world with KOL insight and the key industry and investors.
Speakers

Justin Sperry
Vice President, Transformational Technology for Biotherapeutics & Vaccines,
Pfizer

Mark Emalfarb
CEO & Founder,
Dyadic International Inc.

Mauricio Futran
VP of Advanced Technology, Global Tech Services, Janssen Supply Chain, Johnson & Johnson

Rahul Singhvi
Co-Founder & CEO
Resilience
Co-Founder & CEO
Resilience

Michael P. Angelastro
Director, Division of Pharmaceutical Countermeasures Infrastructure (PCI) Biomedical Advanced Research & Development Authority (BARDA)

Stelios C. Tsinontides
Director
Office of Pharmaceutical Manufacturing Assessment (OPMA)
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research (CDER)
U.S. Food and Drug Administration

Chris Yochim
Head of Business Development,
National Institute for Innovation in Manufacturing BioPharmaceuticals - NIIMBL

Alberto Cuitiño
Interim Dean, Rutgers School of Engineering
Department Chair, Professor
Mechanical & Aerospace Engineering,
Rutgers University

Stephen Chambers
General Partner,
SOSV, &
Managing Partner,
IndieBio NY

Timothy B. Rollender
Director – Venture Programs
New Jersey Economic Development Authority (NJEDA)

Cedric Bisson
Partner,
Teralys Capital,

Shiv Krishnan
Head, External Innovation, Biologics R&D,
Lonza

Frank Gupton
Co-Founder, Phlow Corp., &
CEO, Medicines for All

Sarfaraz Niazi
Adj. Professor of Pharmaceutical Sciences, University of Illinois,
&
CSO, Novel351K

Parviz A. Shamlou
VP & Executive Director, Jefferson Institute of Bioprocessing
(JIB)

Fernando Muzzio
Distinguished Professor of Chemical and Biochemical Engineering,
Rutgers University

Christian Hinrichs
Chief, Cancer Immunotherapy Section at Rutgers Cancer Institute of New Jersey

Renata Pasqualini
Chief Scientific Officer and Founder,
PhageNova Bio

Don Liu
Chief Science Officer,
Naki Therapeutics

Hemanth Kaligotla
Director External Innovation, Bio R&D,
Lonza

Diane Burgess
Board of Trustees Distinguished Prof. of Pharmaceutics, Pfizer Distinguished Endowed Chair in Pharmaceutical Technology, Dept. of Pharmaceutical Sciences, University of Connecticut

Timothy T. Belski, MS, PMP
Branch Chief, BioMaP
PCI ,
Biomedical Advanced Research & Development Authority (BARDA)

Vince Smeraglia
Executive Director,
Strategic Alliances
The Office For Research
Rutgers University

Vipul Davé, Ph.D.
Senior Engineering Fellow,
Strategy, Innovation & Deployment, Johnson & Johnson Supply Chain

Haro
Hartounian
CEO,
BioCentriq

Alastair Florence
Director, Future Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub

Doug Hausner
Senior Manager Business Development, Continuous Manufacturing,
Thermofisher Scientific

Donald Zinn
Vice President,
US Business
Crossject

Jens Bukrinsky
Head of Research,
SB 3000

Kevin Noonan
Partner, Chair of the Biopharmaceuticals Practice Group, McDonnell Boehnen Hulbert & Berghoff LLP

Roop Chandwani
Chief Executive Officer,
Mazards

Leah Stilwell
Senior Director Business Development
Asymchem Group
Program
Day I - Thursday July 7
08:00 Registration & Coffee
09:00 EDT
-
Welcome & Opening Remarks
-
Christian J. Suojanen, CEO, Broadreach Global
-
Alberto Cuitiño, Interim Dean, Rutgers School of Engineering Department Chair, Professor, Mechanical & Aerospace Engineering, Rutgers University
-
Chris Yochim, Head of Business Development, National Institute for Innovation in Manufacturing Biopharmaceuticals - NIIMBL
Judith Sheft, Executive Director New Jersey Commission on Science, Innovation and Technology
-
09:15 EDT
-
Meeting vaccine & pharmaceutical demand, nationally & worldwide. Needs, Challenges & Strategies.
-
KEYNOTE - Timothy T. Belski, MS, PMP, Branch Chief, BioMaP, Division of Pharmaceutical Countermeasures Infrastructure (PCI) Biomedical Advanced Research & Development Authority (BARDA), Assistant Secretary for Preparedness & Response (ASPR), U.S. Department of Health & Human Services
-
PANEL DISCUSSION
-
Cedric Bisson, Partner, Teralys Capital, Co-Chairman of the Canadian Emergency Covid Therapeutics Task Force, Member of the Bio-Manufacturing Emergency Task Force
-
Derron Stark, Partner, Transaction Strategy & Execution, Supply Chain, Health Sciences & Wellness, EY Parthenon
-
-
10:15 EDT
-
CDER efforts on enabling pharmaceutical advanced manufacturing.
-
Stelios C. Tsinontides, Ph.D., FAIChE, Director, Office of Pharmaceutical Manufacturing Assessment (OPMA), OPQ/Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration - FDA
-
10:45 Coffee Break
11:15 EDT
-
Reinventing biologic vaccine and drug development & production.
-
Mark Emalfarb, Founder, CEO & Board Member, Dyadic International (NASDAQ:DYAI)
-
11:35 EDT
-
Acceleration biosimilars development & approvals.
-
Sarfaraz Niazi, Adjunct Professor of Pharmaceutical Sciences, University of Illinois, Chicago, Co-founder & CSO, Novel351k
-
12:00 Networking Lunch
13:00 EDT
-
Continuous API Manufacturing.
-
Alastair Florence, Director, Future Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub, University of Strathclyde
-
13:20 EDT
-
Building Resilience through Excellence in Biomanufacturing.
-
Rahul Singhvi, Co-Founder & CEO, Resilience
-
13:50 EDT
-
IP Issues: Driving innovation & preserving global access in light of the covid IP waiver.
-
Kevin Noonan, Partner, Head of the Biopharmaceutical Practice Group, MBHB LLP, Co-Editor, Patent Docs
-
14:20 EDT
-
INNOVATION SESSIONS
-
NAKI Therapeutics - Don Liu, Chief Science Officer
-
PhageNova Bio - Renata Pasqualini, Chief Scientific Officer and Founder
-
Q&A Panel
-
Shiv Krishnan, Head, External Innovation, Biologics R&D,, Lonza
-
Roop Chandwani, Chief Executive Officer,, Mazards
-
-
-
15:00 Coffee Break
15:30 EDT
-
Building for Success in Bio-Manufacturing Spinouts
-
Moderator: Chris Yochim, Director of Business Development, National Institute for Innovation in Manufacturing Biopharmaceuticals – NIIMBL
-
Haro Hartounian, CEO, BioCentriq
-
Fernando Muzzio, Distinguished Professor of Chemical & Biochemical Engineering, Rutgers University
-
Alastair Florence, Director, Future Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub, University of Strathclyde
-
Vince Smeraglia, Executive Director, Strategic Alliances, The Office for Research, Rutgers University
-
-
16:15 EDT
-
Industry perspectives: innovation and partnering in advanced manufacturing.
-
Justin Sperry, Vice President – Transformational Technology for Biotherapeutics and Vaccines, Worldwide Research, Development and Medical, Pfizer
-
Hemanth Kaligotla, Director External Innovation, Bio R&D, Lonza
-
Leah Stilwell, Senior Director of Business Development, Asymchem Group
-
Douglas Hausner, Senior Manager, Continuous Manufacturing Business Development, Thermo Fisher Scientific
-
17:15 End of Day I Program - Reception (to 19:00 / 7:00PM)
Day II - Friday July 8
08:15 Registration & Coffee
09:00 EDT
-
Opening remarks
09:15 EDT
-
Driving innovation in advanced manufacturing through industry-university collaborations - getting it right.
-
Vipul Davé, Ph.D., Senior Engineering Fellow,Strategy, Innovation & Deployment, Johnson & Johnson Supply Chain
-
Fernando Muzzio, Distinguished Professor of Chemical & Biochemical Engineering, Rutgers University
-
09:45 EDT
-
Fostering brain capital to drive the bio-manufacturing revolution - industry training.
-
Parviz A. Shamlou, Vice President & Executive Director, Jefferson Institute of Bioprocessing (JIB), Thomas Jefferson University
-
10:00 Coffee Break
10:30 EDT
-
End to end continuous manufacturing of liquid products.
-
Diane Burgess, Board of Trustees Distinguished Professor of Pharmaceutics, Pfizer Distinguished Endowed Chair in Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Connecticut
-
10:50 EDT
-
Innovation in cell & gene therapy.
-
Christian Hinrichs, Chief, Cancer Immunotherapy Section at Rutgers Cancer Institute of New Jersey
-
11:15 EDT
-
Needle free delivery of biologics - Crossject & the $60 to $155m BARDA deal.
-
Donald Zinn, Vice President, US Business, Crossject
-
11:30 EDT
-
VC, Corporate & Public Investment in advanced bio-manufacturing - Models & Interest.
-
Justin Sperry, Vice President – Transformational Technology for Biotherapeutics and Vaccines, Worldwide Research, Development and Medical, Pfizer
-
Stephen Chambers, General Partner – SOSV, & Managing Director, IndieBio NY
-
Tim Rollender, Director - Venture Programs at New Jersey Economic Development Authority (NJEDA)
-
12:30 Closing Remarks (12:45 End of Program - Networking)

Addressing Key issues including:
-
Ensuring stable, resilient supply chains,
-
Ensuring sufficient supply of innovative medicines and vaccines?
-
How to efficiently re-shore production
-
On-shoring for the first time and rapidly building capacity.
-
Co-development & partnering models, manufacturing & therapeutics development
-
Partnering with industry
-
Transformational new technologies
-
Technology leapfrogging with innovative technologies and turn-key solutions?
-
Breakthrough innovations in continuous manufacturing of API, end to end production of liquid products, continuous production of biologicals, from peptides to mRNA.
-
Technology and Partnering interests of pharma and industry.
-
Investor interests & opportunities.
-
Working with regulators to enable re-shoring via advanced manufacturing?
-
IP issues with regard to protecting and driving innovation, and ensuring global access?
-
The best models for transferring knowledge and industrial know-how.
-
Effective workforce development for scale up.